| A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment (NCT07393659) | ViiV Healthcare | 2026-07-21 |
| A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed (NCT07650916) | ViiV Healthcare | 2026-06-25 |
| Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184 (NCT07636928) | ViiV Healthcare | 2026-06-04 |
| A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants (NCT07525544) | ViiV Healthcare | 2026-05-14 |
| A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 (NCT07275606) | ViiV Healthcare | 2026-04-15 |
| A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) (NCT07202546) | ViiV Healthcare | 2026-02-11 |
| A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV (NCT07053384) | ViiV Healthcare | 2025-07-10 |
| A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults (NCT07066722) | ViiV Healthcare | 2025-07-07 |
| A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV (NCT06970223) | ViiV Healthcare | 2025-04-22 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults (NCT06786520) | ViiV Healthcare | 2025-01-17 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M) (NCT06741397) | ViiV Healthcare | 2024-12-20 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV (NCT06724640) | ViiV Healthcare | 2024-12-16 |
| A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (NCT06694805) | ViiV Healthcare | 2024-12-02 |
| A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV (NCT06652958) | ViiV Healthcare | 2024-10-02 |
| VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI) (NCT06533280) | ViiV Healthcare | 2024-08-02 |
| Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) (NCT06134362) | ViiV Healthcare | 2024-05-14 |
| A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants (NCT06368986) | ViiV Healthcare | 2024-04-17 |
| First Time in Human Study of Long Acting VH4524184 Formulations (NCT06310551) | ViiV Healthcare | 2024-03-21 |
| A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants (NCT06310616) | ViiV Healthcare | 2024-03-06 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy (NCT05979311) | ViiV Healthcare | 2024-02-21 |
| VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1 (NCT06214052) | ViiV Healthcare | 2024-02-07 |
| A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 (NCT06061081) | ViiV Healthcare | 2023-12-21 |
| A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants (NCT06168318) | ViiV Healthcare | 2023-12-18 |
| Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults (NCT06039579) | ViiV Healthcare | 2023-10-25 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults (NCT06012136) | ViiV Healthcare | 2023-08-24 |
| A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) (NCT05996471) | ViiV Healthcare | 2023-08-17 |
| A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF (NCT05911360) | ViiV Healthcare | 2023-07-07 |
| A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (NCT05917509) | ViiV Healthcare | 2023-07-06 |
| Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics (NCT05674656) | ViiV Healthcare | 2023-07-06 |
| A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation (NCT05776108) | ViiV Healthcare | 2023-03-23 |
| A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity (NCT05631704) | ViiV Healthcare | 2022-12-02 |
| Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study (NCT05896748) | ViiV Healthcare | 2022-11-08 |
| A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (NCT05514509) | ViiV Healthcare | 2022-10-28 |
| First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants (NCT05393271) | ViiV Healthcare | 2022-10-03 |
| A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (NCT05418868) | ViiV Healthcare | 2022-06-14 |
| A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States (NCT05374525) | ViiV Healthcare | 2022-05-18 |
| A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants (NCT05291520) | ViiV Healthcare | 2022-02-23 |
| First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants (NCT05163522) | ViiV Healthcare | 2021-12-13 |
| Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) (NCT04982445) | ViiV Healthcare | 2021-11-18 |
| A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants (NCT05896761) | ViiV Healthcare | 2021-10-28 |
| A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (NCT04900038) | ViiV Healthcare | 2021-08-18 |
| A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults (NCT04871113) | ViiV Healthcare | 2021-06-22 |
| A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants (NCT04827134) | ViiV Healthcare | 2021-05-07 |
| Low-dose Fostemsavir Extended Release Relative Bioavailability Study (NCT04757974) | ViiV Healthcare | 2021-03-05 |
| Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults (NCT04425902) | ViiV Healthcare | 2020-12-16 |
| A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults (NCT04493216) | ViiV Healthcare | 2020-11-18 |
| A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (NCT04542070) | ViiV Healthcare | 2020-11-09 |
| Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin (NCT04563845) | ViiV Healthcare | 2020-11-09 |
| Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) (NCT04630002) | ViiV Healthcare | 2020-10-28 |
| A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries (NCT04399551) | ViiV Healthcare | 2020-09-28 |
| Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254 (NCT04507321) | ViiV Healthcare | 2020-09-24 |
| Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants (NCT04371380) | ViiV Healthcare | 2020-09-16 |
| GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers (NCT04493684) | ViiV Healthcare | 2020-07-31 |
| Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants (NCT04484337) | ViiV Healthcare | 2020-07-31 |
| A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants (NCT04263142) | ViiV Healthcare | 2020-01-27 |
| Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women (NCT03564613) | ViiV Healthcare | 2019-11-18 |
| Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA) (NCT04021290) | ViiV Healthcare | 2019-11-11 |
| A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants (NCT04128293) | ViiV Healthcare | 2019-10-08 |
| Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US) (NCT04001803) | ViiV Healthcare | 2019-07-08 |
| Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults (NCT03945981) | ViiV Healthcare | 2019-07-02 |
| Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent (NCT03984838) | ViiV Healthcare | 2019-06-17 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study (NCT03984812) | ViiV Healthcare | 2019-06-17 |
| Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive (NCT03984825) | ViiV Healthcare | 2019-06-13 |
| Dolutegravir Pediatric Liquid Formulation Study (NCT03921723) | ViiV Healthcare | 2019-05-07 |
| Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents (NCT03682848) | ViiV Healthcare | 2019-05-06 |
| Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine (NCT03836729) | ViiV Healthcare | 2019-02-11 |
| A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults (NCT03784079) | ViiV Healthcare | 2019-01-31 |
| Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG) (NCT03816696) | ViiV Healthcare | 2019-01-23 |
| Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany (NCT03754803) | ViiV Healthcare | 2018-11-08 |
| Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study (NCT03639311) | ViiV Healthcare | 2018-09-24 |
| Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1 (NCT03518060) | ViiV Healthcare | 2018-06-25 |
| A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254 (NCT03575962) | ViiV Healthcare | 2018-06-18 |
| A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men (NCT03422172) | ViiV Healthcare | 2018-04-10 |
| To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers (NCT03441984) | ViiV Healthcare | 2018-02-26 |
| Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) (NCT03446573) | ViiV Healthcare | 2018-01-18 |
| Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection (NCT03400293) | ViiV Healthcare | 2018-01-18 |
| Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults (NCT03299049) | ViiV Healthcare | 2017-10-27 |
| GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers (NCT03231943) | ViiV Healthcare | 2017-09-19 |